Coya Therapeutics, Inc. (COYA)
COYA Stock Price Chart
Explore Coya Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze COYA price movements and trends.
COYA Company Profile
Discover essential business fundamentals and corporate details for Coya Therapeutics, Inc. (COYA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Dec 2022
Employees
8.00
Website
https://www.coyatherapeutics.comCEO
Arun Swaminathan
Description
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
COYA Financial Timeline
Browse a chronological timeline of Coya Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.36, while revenue estimate is $130.00k.
Earnings released on 12 May 2026
EPS came in at -$0.32 surpassing the estimated -$0.39 by +17.95%, while revenue for the quarter reached $300.00k , beating expectations by +100.00%.
Earnings released on 16 Mar 2026
EPS came in at -$0.34 falling short of the estimated -$0.27 by -24.77%, while revenue for the quarter reached $4.00m , beating expectations by +78.04%.
Earnings released on 12 Nov 2025
EPS came in at -$0.10 falling short of the estimated $0.02 by -600.00%, while revenue for the quarter reached $3.56m , beating expectations by +85.14%.
Earnings released on 12 Aug 2025
EPS came in at -$0.36 falling short of the estimated -$0.22 by -63.64%, while revenue for the quarter reached $163.62k , missing expectations by -79.11%.
Earnings released on 13 May 2025
EPS came in at -$0.44 matching the estimated -$0.44, while revenue for the quarter reached $257.88k , missing expectations by -90.21%.
Earnings released on 18 Mar 2025
EPS came in at -$0.18 surpassing the estimated -$0.26 by +30.77%, while revenue for the quarter reached $1.95k , missing expectations by -98.05%.
Earnings released on 6 Nov 2024
EPS came in at -$0.26 surpassing the estimated -$0.41 by +36.59%.
Earnings released on 12 Aug 2024
EPS came in at -$0.19 falling short of the estimated -$0.14 by -35.71%, while revenue for the quarter reached $3.43m , beating expectations by +24.56%.
Earnings released on 9 May 2024
EPS came in at -$0.35 falling short of the estimated -$0.30 by -16.67%, while revenue for the quarter reached $126.84k .
Earnings released on 19 Mar 2024
EPS came in at $0.15 falling short of the estimated $0.26 by -42.31%, while revenue for the quarter reached $6.00m , missing expectations by -19.97%.
Earnings released on 8 Nov 2023
EPS came in at -$0.34 surpassing the estimated -$0.37 by +8.11%.
Earnings released on 8 Aug 2023
EPS came in at -$0.31 surpassing the estimated -$0.32 by +3.13%.
Earnings released on 10 May 2023
EPS came in at -$0.28 surpassing the estimated -$0.43 by +34.88%.
Earnings released on 29 Mar 2023
EPS came in at -$0.42 .
Earnings released on 30 Dec 2022
EPS came in at -$0.52 .
Earnings released on 30 Sept 2022
EPS came in at -$0.42 .
Earnings released on 31 Mar 2022
EPS came in at -$0.26 .
Earnings released on 31 Dec 2021
EPS came in at -$0.25 .
Earnings released on 30 Sept 2021
EPS came in at -$0.14 .
COYA Stock Performance
Access detailed COYA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
